In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

The 5th iPSC Drug Development Summit serves as a pivotal platform for uniting iPSC-based drug developers across the value ...

At ASCO 2025, Servier presented data in the IDH-mutated cancer space.

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

Europe follows a similar pattern, with data from the EU Clinical Trials Information System (CTIS) estimating that less than 0 ...